Journal ID (nlm-ta): PLoS Med
Journal ID (iso-abbrev): PLoS Med
Journal ID (publisher-id): plos
Journal ID (pmc): plosmed
Title:
PLoS Medicine
Publisher:
Public Library of Science
(San Francisco, CA USA
)
ISSN
(Print):
1549-1277
ISSN
(Electronic):
1549-1676
Publication date
(Electronic):
29
November
2016
Publication date Collection:
November
2016
Volume: 13
Issue: 11
Electronic Location Identifier: e1002184
Affiliations
[1
]Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva,
Switzerland
[2
]Infectious Diseases Department, Austin Health, Heidelberg, Australia
Author notes
I have read the journal's policy and have the following conflicts to report: SH and
AJS participated in an investigator-initiated study on the burden of antimicrobial
resistance (TIMBER) supported by an unrestricted research grant provided by Pfizer
Europe and bioMérieux. SH is also a member of the Editorial Board of PLOS Medicine.
AJS is an employee of Hand Hygiene Australia, a national quality improvement program,
and is a member of the Healthcare Associated Infection Advisory Committee of the Australian
Commission for Safety and Quality in Healthcare.
Author information
Article
Publisher ID:
PMEDICINE-D-16-02737
DOI: 10.1371/journal.pmed.1002184
PMC ID: 5127510
PubMed ID: 27898664
SO-VID: 6e059a44-a140-492b-ba8a-264aeb6f81a6
Copyright © © 2016 de Kraker et al
License:
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
For MdK and SH, the research leading to this viewpoint has received support from the
Innovative Medicines Initiative Joint Undertaking under grant agreements nos. 115523,
115620, and 115737 (Combatting Bacterial Resistance in Europe projects [COMBACTE]),
resources of which are composed of financial contribution from the European Union's
7th Framework Programme (FP7/2007–2013) and the European Federation of Pharmaceutical
Industries and Associations (EFPIA) companies’ in kind contribution. The funders had
no role in data collection and analysis, decision to publish, or preparation of the
manuscript.
Subject:
Essay
Subject:
Biology and Life Sciences
Subject:
Microbiology
Subject:
Microbial Control
Subject:
Antimicrobial Resistance
Subject:
Medicine and Health Sciences
Subject:
Pharmacology
Subject:
Antimicrobial Resistance
Subject:
People and Places
Subject:
Demography
Subject:
Death Rates
Subject:
Biology and Life Sciences
Subject:
Population Biology
Subject:
Population Metrics
Subject:
Death Rates
Subject:
Medicine and Health Sciences
Subject:
Hematology
Subject:
Bloodstream Infections
Subject:
Medicine and Health Sciences
Subject:
Health Care
Subject:
Health Care Facilities
Subject:
Hospitals
Subject:
Medicine and Health Sciences
Subject:
Pulmonology
Subject:
Respiratory Infections
Subject:
Lower Respiratory Tract Infections
Subject:
Medicine and Health Sciences
Subject:
Public and Occupational Health
Subject:
Biology and life sciences
Subject:
Organisms
Subject:
Bacteria
Subject:
Staphylococcus
Subject:
Staphylococcus aureus
Subject:
Methicillin-resistant Staphylococcus aureus
Subject:
Biology and life sciences
Subject:
Microbiology
Subject:
Medical microbiology
Subject:
Microbial pathogens
Subject:
Bacterial pathogens
Subject:
Staphylococcus
Subject:
Staphylococcus aureus
Subject:
Methicillin-resistant Staphylococcus aureus
Subject:
Medicine and health sciences
Subject:
Pathology and laboratory medicine
Subject:
Pathogens
Subject:
Microbial pathogens
Subject:
Bacterial pathogens
Subject:
Staphylococcus
Subject:
Staphylococcus aureus
Subject:
Methicillin-resistant Staphylococcus aureus
Subject:
Physical Sciences
Subject:
Mathematics
Subject:
Statistics (Mathematics)
Subject:
Confidence Intervals